A newly developed antibiotic called EVG7 could offer a powerful new way to stop Clostridioides difficile, a dangerous gut bacterium that often returns after treatment. In mouse studies, researchers ...
Affecting roughly half a million Americans each year, bacterial infections caused by Clostridioides difficile—commonly known ...
A novel vaccination approach developed by Vanderbilt Health researchers cleared the harmful gut bacterium Clostridioides difficile (C. diff) in an animal model of infection. An experimental vaccine ...
ARLINGTON, Va. (April 12, 2023) — Five medical organizations say it is essential that hospitals establish antimicrobial stewardship programs to prevent Clostridioides difficile (C. difficile) ...
Paul Feuerstadt, MD, FACG, AGAF, discusses how testing for Clostridioides difficile is recommended for hospitalized patients or outpatients with new-onset, unexplained diarrhea who have risk factors ...
Citing outbreaks of Clostridioides difficile infection in both America and Europe, the researchers emphasized the need for more effective treatments. Exploring how short-chain fatty acids (SCFA) ...
A variety of symptoms can be experienced, from mild diarrhea to severe colon damage. In addition, the use of antibiotics is often associated with the development of C. difficile illness. This disease ...
REBYOTA is indicated for the prevention of recurrence of Clostridioides difficile (C. diff) infection in individuals 18 years of age and older, following antibiotic treatment for recurrent C. diff ...
A total of 54% of adults in the United States were “not at all” familiar with clostridioides difficile (C. diff), a bacterial infection that causes nearly 30,000 deaths in the US each year, according ...
Clostridium difficile bacteria, computer illustration. C. difficile is a normal inhabitant of the human intestine, but it can become a pathogen when antibiotics disrupt the normal intestinal flora and ...
InvestorsHub on MSN
Acurx Pharmaceuticals reports stronger cash position and clinical progress in Q4 2025
Acurx Pharmaceuticals (NASDAQ:ACXP) reported fourth-quarter and full-year 2025 results highlighting a stronger cash position ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results